Insider · CIK 0001653967
Michal Votruba
Files at BTAIQ (BioXcel Therapeutics, Inc.). First filing -, latest -.
In brief
Michal Votruba files SEC Form 4 as director at BTAIQ (BioXcel Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Michal Votruba has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jan 12, 2026 |
Questions about Michal Votruba
Answered from the filings on this page, as of the latest one.
Is Michal Votruba buying or selling?
Michal Votruba has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Michal Votruba's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michal Votruba has 0.
Where does Michal Votruba file Form 4?
Michal Votruba has filed Form 4 at BTAIQ (BioXcel Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.